File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The mifepristone-inducible gene regulatory system in mouse models of disease and gene therapy

TitleThe mifepristone-inducible gene regulatory system in mouse models of disease and gene therapy
Authors
Issue Date2002
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/semcdb
Citation
Seminars In Cell And Developmental Biology, 2002, v. 13 n. 2, p. 143-149 How to Cite?
AbstractThe mifepristone (Mfp)-inducible gene regulatory system is designed to allow control of the spatiotemporal expression of transgenes in vivo in a ligand-dependent manner. This regulatory system is composed of two components: (1) a chimeric transactivator protein that activates transgene transcription only in the presence of the progesterone anatagonist Mfp, and (2) a target transgene placed in the context of a promoter which is responsive only to the Mfp-bound chimeric transactivator. Incorporation of the components of the Mfp-inducible gene regulatory system into transgenic mice has resulted in the establishment of several novel, Mfp-dependent models of disease. Similarly, adaptation of the Mfp-inducible system for use in gene knockout models has resulted in the development of new gene ablation technology which is both tissue-specific and Mfp-dependent. Additionally, the Mfp-inducible gene regulatory system has been used in animal experiments involving somatic gene therapy, where it has shown considerable promise in the regulation of both reporter and therapeutic gene expression. This review focuses on recent application of the Mfp-inducible system to transgenic models, gene knockout models, and somatic gene therapy experiments. In so doing, it demonstrates the considerable promise that future use of this system holds for better understanding and treatment of human disease. © Elsevier Science Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/172807
ISSN
2015 Impact Factor: 5.181
2015 SCImago Journal Rankings: 4.033
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgan, ESWen_US
dc.contributor.authorSchillinger, Ken_US
dc.contributor.authorDemayo, Fen_US
dc.contributor.authorTsai, SYen_US
dc.date.accessioned2012-10-30T06:25:01Z-
dc.date.available2012-10-30T06:25:01Z-
dc.date.issued2002en_US
dc.identifier.citationSeminars In Cell And Developmental Biology, 2002, v. 13 n. 2, p. 143-149en_US
dc.identifier.issn1084-9521en_US
dc.identifier.urihttp://hdl.handle.net/10722/172807-
dc.description.abstractThe mifepristone (Mfp)-inducible gene regulatory system is designed to allow control of the spatiotemporal expression of transgenes in vivo in a ligand-dependent manner. This regulatory system is composed of two components: (1) a chimeric transactivator protein that activates transgene transcription only in the presence of the progesterone anatagonist Mfp, and (2) a target transgene placed in the context of a promoter which is responsive only to the Mfp-bound chimeric transactivator. Incorporation of the components of the Mfp-inducible gene regulatory system into transgenic mice has resulted in the establishment of several novel, Mfp-dependent models of disease. Similarly, adaptation of the Mfp-inducible system for use in gene knockout models has resulted in the development of new gene ablation technology which is both tissue-specific and Mfp-dependent. Additionally, the Mfp-inducible gene regulatory system has been used in animal experiments involving somatic gene therapy, where it has shown considerable promise in the regulation of both reporter and therapeutic gene expression. This review focuses on recent application of the Mfp-inducible system to transgenic models, gene knockout models, and somatic gene therapy experiments. In so doing, it demonstrates the considerable promise that future use of this system holds for better understanding and treatment of human disease. © Elsevier Science Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/semcdben_US
dc.relation.ispartofSeminars in Cell and Developmental Biologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshDisease Models, Animalen_US
dc.subject.meshGene Therapy - Methodsen_US
dc.subject.meshGene Transfer Techniquesen_US
dc.subject.meshGenetic Techniquesen_US
dc.subject.meshHormone Antagonists - Pharmacologyen_US
dc.subject.meshLigandsen_US
dc.subject.meshMiceen_US
dc.subject.meshMifepristone - Pharmacologyen_US
dc.subject.meshModels, Geneticen_US
dc.subject.meshTransgenesen_US
dc.titleThe mifepristone-inducible gene regulatory system in mouse models of disease and gene therapyen_US
dc.typeArticleen_US
dc.identifier.emailNgan, ESW: engan@hkucc.hku.hken_US
dc.identifier.authorityNgan, ESW=rp00422en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S1084-9521(02)00020-4en_US
dc.identifier.pmid12240599-
dc.identifier.scopuseid_2-s2.0-0036426628en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036426628&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume13en_US
dc.identifier.issue2en_US
dc.identifier.spage143en_US
dc.identifier.epage149en_US
dc.identifier.isiWOS:000177762200011-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridNgan, ESW=22234827500en_US
dc.identifier.scopusauthoridSchillinger, K=6603467008en_US
dc.identifier.scopusauthoridDeMayo, F=7005462358en_US
dc.identifier.scopusauthoridTsai, SY=7403478781en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats